Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival when treated with chemoradiation compared to definitive radiation alone. Treatment with concurrent or sequential CRT was associated with a 33% reduction in the risk of death.
A 12-week physical and psycho-social intervention improved functional capacity in advanced lung cancer patients, while also enhancing their quality of life. The study's findings suggest that exercise interventions can be a beneficial approach for these patients, reducing the burden on caregivers and improving overall well-being.
A community-based intervention called c-CARE improved cancer literacy and reduced disparate lung cancer outcomes among minority communities. The study found that participants showed increased knowledge and self-efficacy for lung cancer screening, but not perceived susceptibility.
A study analyzing over 1.1 million NSCLC cases found significant disparities in survival rates based on race and socioeconomic factors such as education level and income. Patients of Asian and Hispanic backgrounds had better overall survival rates compared to Whites and Blacks.
A study integrating smoking cessation programs with low-dose CT lung cancer screenings found that this approach can decrease mortality rates while being relatively cost-effective. The research suggests that adding a robust smoking cessation intervention to an organized LDCT screening program could result in significantly fewer deaths, ...
A study published at the International Association for the Study of Lung Cancer (IASLC) conference found that biopsy specimens are a reliable material for evaluating DLL3 expression in small cell lung cancer. High levels of DLL3 expression were correlated with poor survival trends, smoking history, and neuroendocrine differentiation.
A study published in the IASLC 18th World Conference on Lung Cancer found that early specialist palliative care for recently diagnosed malignant pleural mesothelioma (MPM) patients does not impact quality of life. Researchers concluded that there is no role for routine early referral to palliative care, regardless of symptoms.
Researchers confirmed IASLC's proposed criteria for uncertain resection margin status (R(un)) have a prognostic value between R0 and R1. The study analyzed data from 14,712 patients and evaluated the impact of various factors on survival.
Researchers found that treating stage II and III non-small cell lung cancer (NSCLC) patients with chemotherapy based on their specific BRCA1 expression levels did not increase overall survival rates. However, BRCA1 expression levels were found to be prognostic, and individualized treatment could achieve different outcomes.
Lung cancer clinical trials have complex requirements that act as a barrier to development and patient enrollment. A retrospective study found an increase in eligibility criteria for medical therapy trials, particularly for cardiac, concurrent medications, and immunotherapy-related treatments.
The IASLC published a comprehensive summary of the year's key developments in thoracic oncology, covering prevention, early detection, pathology, staging, surgery, adjuvant therapy, radiotherapy, and immunotherapy. The publication highlights significant progress in small cell lung cancer and malignant mesothelioma.
A retrospective study found that treatment improved overall survival in elderly patients with early-stage esophageal cancer. Surgery and local therapies such as chemoradiation showed significantly improved five-year overall survival rates compared to observation, with a median age of 84 years.
A new study has found that radiotherapy for invasive breast cancer increases the risk of developing second primary lung cancer. The research, conducted in Taiwan, involved analyzing data from over 986,000 patients with breast cancer between 2000 and 2010. The results showed a significant increase in lung cancer incidence among women wh...
A study found that elderly non-small cell lung cancer (NSCLC) patients experiencing definitive radiation had a lower incidence of esophagitis compared to younger patients. The study, published in the Journal of Thoracic Oncology, showed an inverse correlation between age and rate of esophagitis for both grade levels.
According to a study published in Journal of Thoracic Oncology, advanced stage Non-Small Cell Lung Cancer (NSCLC) patients receiving standard of care treatment have significantly longer overall survival rates compared to those not receiving treatment. This trend is observed across various stages of the disease.
A study analyzing 740 early-stage NSCLC patients treated with SBRT found that Squamous Cell Carcinoma (SqCC) has a significantly higher rate of local failure compared to other histological subtypes. SqCCs are more resistant to SBRT, which may require treatment optimization based on histological subtype.
French researchers report harmonization study on PD-L1 immunohistochemistry testing in NSCLC. Durvalumab shows clinical activity and well-tolerability in heavily-pretreated patients with NSCLC. Patients receiving pembrolizumab report better quality of life than those on chemotherapy.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
Public health advocates from around the world are using various tactics to reduce tobacco company influence, including pension fund reform and smoke-free legislation. Efforts have shown positive impacts on public health, such as a 13% decrease in all-cause mortality in Ireland.
Researchers and patient advocates emphasize the importance of new care models in combating lung cancer. Dr. Laurie Gaspar discusses the benefits of shared decision-making and Patient Decision Aids, while Dr. Raymond Osarogiagbon highlights the effectiveness of Center of Excellence programs in underserved areas.
A study of 101 advanced lung cancer patients found that hybrid capture-based next-generation sequencing (HC-based NGS) identified clinically actionable genomic alterations (GAs) in 50% of patients, leading to changes in treatment strategy. The overall response rate to targeted therapies was 65%, with median survival not yet reached.
A randomized controlled trial found that preoperative high-intensity interval training improved aerobic performance in patients with operable non-small cell lung cancer. However, it did not significantly reduce postoperative complications or mortality rates.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
Researchers developed liquid biopsies to detect EGFR mutations in urine, plasma, and blood samples. The tests showed high sensitivity and specificity for identifying patients suitable for targeted treatment and predicting cancer recurrence.
A Swiss analysis found that treating Nivolumab only to patients with positive PD-L1 tests compared to DOC or all patients with NIV is more cost-effective, with ICERs below the WTP threshold. Treating only patients with ?1% or ?10% PD-L1+ with NIV also results in improved cost-effectiveness.
The College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology announced a revised evidence-based guideline for molecular testing in lung cancer patients. The guidelines aim to improve patient selection and targeted therapies.
A large cohort of 29,908 patients with pathologic stage T2N0M0 NSCLC showed improved median overall survival and 5-year OS when receiving adjuvant chemotherapy. The study demonstrated a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size.
The International Association for the Study of Lung Cancer calls on Asian-Pacific governments to take action against lung cancer, citing the need for effective tobacco control, affordable healthcare, and early diagnosis. The goal is to reduce lung cancer deaths by one-third by 2030.
The IASLC consensus statement provides key pathologic, diagnostic, and therapeutic considerations for managing EGFR mutation positive NSCLC patients. It recommends optimal choice of EGFR TKIs, management of brain metastasis, and use of circulating free DNA for molecular studies.
The 2016 Asia Pacific Lung Cancer Conference presented the latest advances in lung cancer research, including immunotherapy and multidisciplinary practices. Tobacco use was also a major concern, with experts emphasizing the need for stricter control measures to reduce deaths from lung cancer in Southeast Asia.
Researchers evaluated an IHC screening tool for ROS1 gene rearrangements in a cohort of 170 patients. The results showed high sensitivity and specificity rates, making it a feasible option for first-line screening in a lung cancer setting.
A study compared four PD-L1 IHC diagnostic assays in lung cancer, demonstrating similarities and differences. The findings support the use of each assay according to its specific indication, recommending utilization for distinct scoring algorithms.
The International Association for the Study of Lung Cancer (IASLC) highlights significant progress in lung cancer prevention, diagnosis, staging, and treatment in 2015. The organization introduces a comprehensive educational resource covering topics such as tobacco control, early detection, and immunotherapy.
Researchers identified a novel mutation in the KIT gene that contributes to crizotinib resistance in ROS1+ non-small cell lung cancer patients. Ponatinib, a KIT tyrosine kinase inhibitor, demonstrates potential as a therapeutic option for overcoming this resistance.
CV screening workstations aid technicians in accurately reviewing LDCT scans, leading to reduced false positives and improved efficiency. The study found 97.8% sensitivity and 98% specificity in identifying abnormal scans, with average review time of 208 seconds.
A cross-sectional survey found that detailed clinician communication can alleviate patient distress associated with incidental pulmonary nodules. Patients who received accurate information about their nodule size and diagnosis had a more reassuring experience, reducing anxiety and improving overall well-being.
The ALCF-IASLC Joint Fellowship Award supports novel research with the potential to positively impact lung cancer patients. Dr. Robin Mjelle's project aims to develop a risk-prediction tool and serum poly-marker kit for early lung cancer detection, leveraging pre-diagnostic serum samples from Norway's HUNT biobank.
A new method using proton nuclear magnetic resonance (H-NMR) of blood plasma identifies unique metabolic biomarkers for early and late-stage lung cancer. The technique correctly classifies 78% of patients and 92% of controls, showing promise as a complementary tool to improve lung cancer screening.
A recent study published in Journal of Thoracic Oncology found that the FDA-approved VENTANA anti-ALK(D5F3)CDx assay is superior to the 5A4 IHC assay for selecting patients with non-small cell lung cancer eligible for ALK tyrosine kinase inhibitor treatment.
Researchers identified 5 autoantibody classifiers that can distinguish lung cancer from smoker controls with high sensitivity and specificity, as well as those from benign lung nodules. These findings have the potential to improve early detection of lung cancer through companion molecular diagnostic modalities.
Afinatinib has shown significant clinical benefits for NSCLC patients with brain metastases, including improved PFS (8.2 vs. 5.4 months) and ORR (73% vs. 25%) compared to standard platinum doublet chemotherapy. The drug's efficacy was particularly notable in patients harboring EGFR Del19 mutations.
Research published in Journal of Thoracic Oncology found that non-small cell lung cancer patients with early-stage tumors had a higher rate of nodal upstaging and longer hospital stays when undergoing open chest surgery compared to video-assisted thoracic surgery (VATS). This study suggests that VATS may not be equivalent to open surge...
A new study reveals that mandatory tumor tissue requirements in clinical trials delay treatment and reduce patient enrollment. Trials without these requirements show faster treatment initiation and higher enrollment rates.
A phase III trial showed that sorafenib modestly increased progression-free survival (PFS) and disease control rate in NSCLC patients, but did not impact overall survival. The study also found that EGFR mutation positive patients receiving sorafenib had significantly longer OS and PFS.
The International Association for the Study of Lung Cancer has released new data for the TNM classification of lung cancer, which will inform the Eighth Edition of the staging manual. The new database includes 94,708 patients diagnosed worldwide from 1999-2010 and analyzes tumor size, lymph node involvement, and metastatic status.
The new 2015 WHO Classification of Lung Tumors provides standard criteria for pathology diagnosis and clinical practice. The updated classification focuses on histologic subtyping and classification according to predominant subtype, leading to multiple new discoveries in lung adenocarcinoma.
The International Association for the Study of Lung Cancer (IASLC) has issued a new statement on tobacco control and smoking cessation, calling for increased taxes on tobacco products to reduce cigarette smoking. The organization also emphasizes comprehensive advertising and promotion bans and product regulation, including pack warnings.
The International Association for the Study of Lung Cancer (IASLC) has selected 5 advocates to attend the 16th World Conference on Lung Cancer, where they will share and learn strategies to increase awareness. The recipients include Hildreth Grossman, Kathleen Mewhiney, Victor Lasebikan, Seda Kansu, and Tetsuya Yamaoka.